Rapid drug detection test DBZ-102

for benzodiazepinesurineimmunoassay

Description
The Benzodiazepines Rapid Test Device (Urine) DBZ-102 is a rapid visual immunoassay for the qualitative presumptive detection of benzodiazepines in human urine specimens. It is designed for initial screening in clinical laboratories, occupational health and point-of-care settings. Positive or unexpected results should be confirmed by a laboratory reference method (GC-MS/LC-MS).

Key features

• Intended use: Qualitative presumptive detection of benzodiazepines in urine
• Test principle: Rapid visual immunoassay
• Sample type: Human urine
• Format: Cassette or strip (product variants available)
• Catalogue code: DBZ-102 (example for benzodiazepines)
• Cutoff: 300 ng/ml (DBZ-102)
• Reported sensitivity: 100 / 200 ng/ml (per product table)
• Packaging: 25 tests per kit (25T/Kit)

Product range (examples)

• BZO | DBZ-102 | 300 ng/ml | Cassette/Strip | 25T/Kit
• Other single-analyte devices available: AMP (DAM-102), COC (DCO-102), THC (DTH-102), FYL (DFY-102), etc.
• Multi-panel options: DOA-123 (2-panel) up to DOA-1123 (12-panel) — dipcard formats available

Applications and usage
Recommended for screening in medical laboratories, emergency departments, occupational health clinics, rehabilitation centers and forensic screening. Use as a rapid presumptive test; follow local protocols for confirmatory testing.

Ordering and packaging

• Standard pack: 25 tests per kit (25T/Kit)
• Available formats: cassette, strip, dipcard and multi-parameter panels
• Consult catalogue codes for ordering specific analytes and cutoff options